Silence Therapeutics plc
SLNCF
$4.00
-$1.50-27.27%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 197.18% | -99.87% | -89.39% | -70.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 197.18% | -99.87% | -89.39% | -70.37% |
| Cost of Revenue | -- | -79.63% | -99.41% | -98.24% | -97.45% |
| Gross Profit | -- | 367.05% | -99.91% | 104.44% | 105.39% |
| SG&A Expenses | -8.07% | -8.56% | -32.62% | -24.71% | -26.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.14% | -40.21% | -50.59% | -11.81% | -4.30% |
| Operating Income | 35.43% | 41.52% | -3,750.91% | 7.25% | 1.88% |
| Income Before Tax | 55.14% | 47.57% | -193.22% | 40.96% | -40.03% |
| Income Tax Expenses | -90.00% | -- | -100.00% | -97.96% | -95.61% |
| Earnings from Continuing Operations | 55.15% | 47.57% | -195.68% | 41.04% | -38.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.15% | 47.57% | -195.68% | 41.04% | -38.47% |
| EBIT | 35.43% | 41.52% | -3,750.91% | 7.25% | 1.88% |
| EBITDA | 35.49% | 41.62% | -6,558.51% | 7.31% | 1.88% |
| EPS Basic | 55.15% | 47.57% | -195.66% | 41.25% | -37.00% |
| Normalized Basic EPS | 52.86% | 47.59% | -193.18% | 41.16% | -31.87% |
| EPS Diluted | 55.15% | 47.57% | -195.66% | 41.25% | -37.00% |
| Normalized Diluted EPS | 52.86% | 47.59% | -193.18% | 41.16% | -31.87% |
| Average Basic Shares Outstanding | 0.01% | 0.02% | 0.01% | 0.36% | 1.06% |
| Average Diluted Shares Outstanding | 0.01% | 0.02% | 0.01% | 0.36% | 1.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |